MedTrace Logo

Abnormal Lipids - Causes and Effects

NCT02195050 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1396

Last updated 2023-05-31

No results posted yet for this study

Summary

1. At target LDL-C levels, apoB100 concentrations will be higher than recommended levels in the following populations:

1. Tertiary centre lipid clinic patients with raised TG treated with statins.
2. Patients with type 2 diabetes treated with statins.
3. Patients with Chronic Kidney disease (CKD) stages 4 and 5 treated with statins.
2. Despite achieving LDL-C and non-HDL-C targets, a significant number of statin-treated patients have residual cardiovascular risk related to raised hsCRP. The relationship between hsCRP and Lp-PLA2 (markers of inflammation) and LDL particle number measured by apoB100 is stronger than that of measured and calculated LDL and non-HDL. In statin treated patients there will be higher levels of hs-CRP and Lp-PLA2 in patients achieving LDL targets but not apo B targets.
3. We hypothesise that non-diabetic patients with severe hypertriglyceridaemia (fasting serum triglyceride \>5.5 mmol/l) have evidence of greater nerve damage compared with matched controls.
4. LAL deficiency is underdiagnosed in patients with severe hypertriglyceridaemia, low HDL-C, hyperlipidaemias, non alcoholic fatty liver disease and idiopathic high liver enzymes.

Conditions

  • Hypertriglyceridaemia

Sponsors & Collaborators

  • Manchester University NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • Handrean Soran, MD FRCP · Manchester University NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-23
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02195050 on ClinicalTrials.gov